



## FOR IMMEDIATE RELEASE

### Company Contacts:

#### Nuvectra Corporation

Walter Berger, Chief Financial Officer  
(972) 668-4106  
wberger@nuvectramed.com

Jennifer Armstrong, Media Relations  
(214) 618-4823  
jarmstrong@nuvectramed.com

### Investor Contacts:

#### The Ruth Group

Brian Johnston  
(646) 536-7028  
bjohnston@theruthgroup.com

Zack Zubow  
(646) 536-7020  
zkubow@theruthgroup.com

## Nuvectra to Report Second Quarter 2017 Financial Results on August 8, 2017

**Plano, Texas, July 25, 2017** – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close.

Nuvectra will hold a conference call on Tuesday, August 8, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 58530044. A live webcast of the conference call will be available on the investor relations section of the Company's website at <http://investors.nuvectramed.com/>.

A replay of the call will be available starting on August 8, 2017 through August 15, 2017. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 58530044. The webcast will be available in the investor relations section of the Company's website for 90 days following the completion of the call.

### About Nuvectra Corporation

Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson's Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at [www.nuvectramed.com](http://www.nuvectramed.com).